Sponsor content

HIV-1 Env Fusion Peptide Immunogens and Their Use - Licensing Opportunity

Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases designed fusion peptide immunogens that were comprised of the exposed residues of the fusion peptide coupled to highly immunogenic carrier proteins to focus the immune response. The fusion peptide can be displayed on scaffold proteins and – when coupled to HIV-1 Env trimer boosts – has the potential to elicit antibodies capable of neutralizing diverse HIV-1 strains in mice, guinea pigs and rhesus macaques, and might therefore serve as the basis for an effective HIV vaccine.

Hybridoma cell lines producing antibodies to RSV NS1: Licensing and Collaboration Opportunity

This technology provides a new set of hybridoma cell lines each expressing a single monoclonal antibody against human respiratory syncytial virus (RSV) nonstructural protein 1 (NS1). These antibodies have variously been shown to detect NS1 protein in an enzyme-linked immunosorbent assay (ELISA), Western blot assay, immunofluorescence microscopy of paraformaldehyde-fixed cells, and flow cytometry. The various antibodies can vary in their efficiency in each of these assays.

Recombinant HIV-1 Envelope Protein for Vaccine Use - Licensing and Collaboration Opportunity

Researchers at the Vaccine Research Center (“VRC”) have determined the three-dimensional structure of the HIV-1 Envelope trimeric ectodomain (“Env”), comprised of three gp120 and three gp41 subunits, in its prefusion, mature, closed conformation. The researchers hypothesize that immunization with the prefusion, closed HIV-1 Env protein will elicit a neutralizing immune response.

Recombinant Respiratory Syncytial Virus Challenge Strain - Licensing and Collaboration Opportunity

This invention relates to a reverse genetics system and cDNA-derived virus for a contemporary wild-type clinical isolate of RSV of antigenic subgroup A, termed RSV strain A/Maryland/001/11. Clinical study material of this challenge virus has been manufactured and is available for use as an U.S. Food and Drug Administration (FDA) regulated Investigational New Drug (IND) in clinical studies in adult volunteers within and outside of the United States.

Use of Rostafuroxin to Inhibit Viral Infection: Collaboration and Licensing Opportunity

NIAID scientists have discovered that Rostafuroxin, a synthetic digitoxigenin derivative, inhibits RSV infection in respiratory epithelial cells by inhibiting the RSV induced ATP1A1-mediated signaling pathway required for RSV entry. Rostafuroxin is a promising anti-viral drug candidate for RSV and possibly other viruses that use the same pathway for host cell entry.

Fusion Glycoprotein Vaccine for Human Metapneumovirus: Licensing Opportunity

Investigators at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have generated an hMPV fusion glycoprotein (“F protein”) stabilized in a prefusion conformation. The prefusion stabilized F protein immunogen can be delivered as either an isolated homotrimer or trimers displayed on a nanoparticle. These immunogens elicit broad and potent hMPV-neutralizing antibodies.

ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN-BARR VIRUS INFECTION: Collaboration and Licensing Opportunity

Scientists at the NIAID are developing neutralizing antibodies, originally isolated from humans or non-human primates, that could be useful in preventing primary infection or reactivation of EBV in immunocompromised individuals. These antibodies are 10-100 times more potent than the most potent EBV neutralizing antibody identified to date (72A1).

Middle East Respiratory Syndrome Coronavirus Antibodies: Collaboration and Licensing Opportunity

Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have identified and developed neutralizing monoclonal antibodies (nMAbs) against the MERS-CoV. In preclinical testing, these nMAbs have demonstrated potent protective effects, preventing death, viral replication in the lower airways and severe disease in challenge studies with mice.

Methods for Dagnosing and Treating Mycobacterium tuberculosis (Mtb) Infection through Detection of CD153 Expression Level: Collaboration and Licensing Opportunity

NIAID researchers have discovered that the expression of TNF superfamily molecule CD153 (TNSF8) is required for control of the pulmonary Mtb infection by CD4 T cells. Since the expression of CD153 by CD4 T cells is a major immune mechanism of host protection against Mtb infection, the discovery can be used to effectively diagnose and treat Mtb infections in the future.

Collaborative Research and Licensing Opportunity: Monoclonal Antibody Specific for DNA/RNA Hybrid Molecules

NIAID has a hybridoma available for non-exclusive licensing that produces a monoclonal antibody specific for DNA/RNA hybrids. The applications for this hybridoma include its use in immuno-fluorescence (IF) microscopy; DNA/RNA immunoprecipitation (DRIP) and also in diagnostic kits for viral/bacterial infections, cancers, and a variety of other human diseases. NIH researchers have also incorporated the antibody into a micro-array platform, expanding its potential for use in diagnostic devices.

Collaborative Research and Licensing Opportunity: Neutralizing Antibodies to Influenza HA and Their Use and Identification

Scientists at NIAID isolated families of antibodies capable of neutralizing diverse group 1 and group 2 influenza A viruses. The antibodies identified precisely targeted parts of the hemagglutinin (HA) protein, present on the surface of the influenza virus, that are least variable from season to season. A passive administration of members of these families of antibodies to individuals would represent an alternative to the current standard of care for severe influenza virus infection.